CORDIS
EU research results

CORDIS

English EN
Establishing the molecular fundamentals of arthritic diseases – a step forward to Heal Arthritis

Establishing the molecular fundamentals of arthritic diseases – a step forward to Heal Arthritis

Objective

In the ArthritisHeal project 7 universities and 2 companies, together with 8 associated partners, will train 12 young researchers and will discover novel therapeutic targets for two rheumatic diseases: osteoarthritis (OA) and rheumatoid arthritis (RA). The project will focus on the role of pro-resolving lipids, which play an important role in both diseases by stimulating resolution of inflammation. Both OA and RA cause pain and deformation of joints, with inflammation playing large role in the pathogenesis of both diseases. Current therapies, focused on inhibition of inflammation, are insufficient to cure rheumatic diseases. By exploiting pro-resolving mechanisms, novel therapeutic targets will be discovered in this project, ultimately improving RA and OA treatment.
During the project both clinical samples and animal models will be used to study mode of action and verify clinically relevant lipids. Novel lipids discovered in pre-clinical models are validated in clinical samples, and the mode-of-action of known lipids will be determined in pre-clinical models.
The consortium of academic and industrial beneficiaries with leading expertise in rheumatology, lipidomics, immunology and data analysis will provide scientific and technology training to ESRs. Associated partners will provide secondment opportunities and training, e.g. in regulatory and IP issues and career development. Each ESR will follow a personalised training programme combining clinical, biological and chemical insights to solve challenges in the development of treatments for rheumatic diseases. The ESRs will receive training both in an academic as well as an industrial setting.
By studying the role of pro-resolving lipids in two important rheumatic diseases in conjunction, the consortium will:
- Train young researchers in the interdisciplinary approach necessary to develop treatments for complex diseases.
- Validate therapeutic targets in important pro-resolving lipid pathways.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN

Address

Albinusdreef 2
2333 Za Leiden

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 796 859,64

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 563 965,92

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 256 320

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 303 172,56

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 252 788,40

QUEEN MARY UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 303 172,56

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 303 172,56

PHARMAGNOSE VIOTECHNOLOGIKI ANONYMI ETAIREIA

Greece

EU Contribution

€ 243 017,64

IMMUNOTECH SAS

France

EU Contribution

€ 274 802,04

Partners (8)

Sort alphabetically

Expand all

PHARMATICS LIMITED

THE SCRIPPS RESEARCH INSTITUTE

ABBVIE INC

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

AB Sciex Pte. Ltd

DEHNE MATTHIAS

STICHTING NATIONAAL REUMAFONDS

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Project information

Grant agreement ID: 812890

Status

Ongoing project

  • Start date

    1 March 2019

  • End date

    28 February 2023

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 297 271,32

  • EU contribution

    € 3 297 271,32

Coordinated by:

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands